Novel-Mechanism Antibacterials And Microbiome-Friendly Agents Now Key For Summit Therapeutics
Rare genetic disorders are no longer in the clinical development mix at Summit, which is hunkering down on identifying novel mechanisms of action for new antibacterials, including the discovery of much-needed agents for gonorrhea and microbiome-friendly agents for gut infections.
You may also be interested in...
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Summit’s utrophin modulator, ezutromid, posted intriguing interim data in January, but failed to meet the primary and all secondary endpoints in a Phase II study. The UK firm discontinued development of ezutromid and will now focus on novel antibiotic candidates.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.